SAREPTA THERAPEUTICS, INC.

Sector revisions Sarepta Therapeutics, Inc.

Equities

SRPT

US8036071004

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 02:30:00 06/12/2025 am IST			5-day change	1st Jan Change
22.26 ^USD	-2.45%		+6.25%	-81.69%

25/11	Sarepta Therapeutics, Inc. Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of Elevidys Gene Therapy for Non-Ambulant Individuals with Duchenne	CI
25/11	Sarepta Therapeutics Receives FDA Approval for Dosing Levels for Elevidys Study to Treat Duchenne Muscular Dystrophy	MT

Sector:

Location:

X axis:

Main competitors

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	1m. Revenue rev.	4m. EPS revision	4m. Revenue rev.	1y. EPS revision	1y. Revenue rev.	Visibility	Nbr of analysts
	SAREPTA THERAPEUTICS, INC.							22
	ULTRAGENYX PHARMACEUTICAL INC.							20
	Average							21
	Weighted average by Cap.							21

Diagnostic & Testing Substances Manufacturers

As early as today, start finding the best investment opportunities!